|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF638 |
Gene summary for ZNF638 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF638 | Gene ID | 27332 |
| Gene name | zinc finger protein 638 | |
| Gene Alias | NP220 | |
| Cytomap | 2p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q14966 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27332 | ZNF638 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.49e-24 | 7.64e-01 | -0.0132 |
| 27332 | ZNF638 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 4.21e-30 | 8.58e-01 | -0.013 |
| 27332 | ZNF638 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.86e-28 | 8.33e-01 | -0.0121 |
| 27332 | ZNF638 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.66e-05 | 6.99e-01 | -0.0961 |
| 27332 | ZNF638 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 2.73e-09 | 7.35e-01 | -0.0876 |
| 27332 | ZNF638 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.75e-05 | 6.61e-01 | -0.0822 |
| 27332 | ZNF638 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 4.81e-07 | 6.87e-01 | -0.0809 |
| 27332 | ZNF638 | C04 | Human | Oral cavity | OSCC | 6.38e-06 | 5.02e-01 | 0.2633 |
| 27332 | ZNF638 | C21 | Human | Oral cavity | OSCC | 6.92e-21 | 8.22e-01 | 0.2678 |
| 27332 | ZNF638 | C30 | Human | Oral cavity | OSCC | 5.76e-08 | 6.46e-01 | 0.3055 |
| 27332 | ZNF638 | C38 | Human | Oral cavity | OSCC | 3.60e-02 | 6.97e-01 | 0.172 |
| 27332 | ZNF638 | C43 | Human | Oral cavity | OSCC | 7.94e-09 | -7.10e-03 | 0.1704 |
| 27332 | ZNF638 | C46 | Human | Oral cavity | OSCC | 2.40e-04 | 2.58e-01 | 0.1673 |
| 27332 | ZNF638 | C57 | Human | Oral cavity | OSCC | 4.50e-02 | 2.47e-02 | 0.1679 |
| 27332 | ZNF638 | C08 | Human | Oral cavity | OSCC | 7.45e-19 | 5.50e-01 | 0.1919 |
| 27332 | ZNF638 | C09 | Human | Oral cavity | OSCC | 3.69e-03 | 1.96e-01 | 0.1431 |
| 27332 | ZNF638 | EOLP-1 | Human | Oral cavity | EOLP | 4.39e-25 | 5.83e-01 | -0.0202 |
| 27332 | ZNF638 | NEOLP-1 | Human | Oral cavity | NEOLP | 1.72e-10 | 5.72e-01 | -0.0194 |
| 27332 | ZNF638 | NEOLP-2 | Human | Oral cavity | NEOLP | 3.14e-12 | 4.92e-01 | -0.0196 |
| 27332 | ZNF638 | NEOLP-3 | Human | Oral cavity | NEOLP | 1.56e-20 | 5.31e-01 | -0.0191 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
| GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
| GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
| GO:00083802 | Colorectum | MSS | RNA splicing | 159/3467 | 434/18723 | 1.75e-19 | 1.22e-16 | 159 |
| GO:00083804 | Colorectum | FAP | RNA splicing | 108/2622 | 434/18723 | 7.90e-10 | 1.86e-07 | 108 |
| GO:00083805 | Colorectum | CRC | RNA splicing | 90/2078 | 434/18723 | 2.80e-09 | 7.97e-07 | 90 |
| GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:00083808 | Lung | IAC | RNA splicing | 75/2061 | 434/18723 | 4.89e-05 | 1.12e-03 | 75 |
| GO:000838013 | Lung | AIS | RNA splicing | 68/1849 | 434/18723 | 8.50e-05 | 2.11e-03 | 68 |
| GO:000838023 | Lung | MIAC | RNA splicing | 44/967 | 434/18723 | 1.56e-05 | 1.07e-03 | 44 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000838025 | Oral cavity | EOLP | RNA splicing | 115/2218 | 434/18723 | 2.24e-17 | 3.04e-14 | 115 |
| GO:000838033 | Oral cavity | NEOLP | RNA splicing | 110/2005 | 434/18723 | 2.29e-18 | 2.72e-15 | 110 |
| GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
| GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
| GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF638 | SNV | Missense_Mutation | c.2614G>C | p.Glu872Gln | p.E872Q | Q14966 | protein_coding | deleterious(0.02) | possibly_damaging(0.494) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF638 | SNV | Missense_Mutation | c.4453N>C | p.Asp1485His | p.D1485H | Q14966 | protein_coding | tolerated(0.09) | probably_damaging(0.921) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF638 | SNV | Missense_Mutation | c.5347N>A | p.Glu1783Lys | p.E1783K | Q14966 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZNF638 | SNV | Missense_Mutation | rs141845828 | c.784A>G | p.Met262Val | p.M262V | Q14966 | protein_coding | tolerated(0.82) | benign(0) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
| ZNF638 | SNV | Missense_Mutation | novel | c.3142N>A | p.Leu1048Ile | p.L1048I | Q14966 | protein_coding | tolerated(0.06) | benign(0.388) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF638 | SNV | Missense_Mutation | c.5252N>G | p.Leu1751Trp | p.L1751W | Q14966 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF638 | SNV | Missense_Mutation | c.522N>C | p.Leu174Phe | p.L174F | Q14966 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ZNF638 | SNV | Missense_Mutation | c.3433G>C | p.Glu1145Gln | p.E1145Q | Q14966 | protein_coding | tolerated(0.05) | benign(0.119) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF638 | SNV | Missense_Mutation | c.4772N>A | p.Gly1591Asp | p.G1591D | Q14966 | protein_coding | deleterious(0.01) | benign(0.074) | TCGA-BI-A0VS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZNF638 | SNV | Missense_Mutation | rs763709853 | c.3500N>C | p.Leu1167Pro | p.L1167P | Q14966 | protein_coding | deleterious(0.04) | benign(0.121) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |